文献速递肿瘤 PET/CT

使用胃泌素释放肽受体拮抗剂68Ga-RM2 PET/CT诊断复发性前列腺癌:[18F]氟乙基胆碱PET/CT阴性或不确定患者的初步结果

Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-18

回顾性研究纳入16例生化复发前列腺癌且18FECH-PET/CT阴性(14例)或不确定(2例)的男性,行全身68Ga-RM2-PET/CT,10/16例(62.5%)发现局灶性异常摄取,其中7例经组织学、定向治疗反应或进一步影像确认。68Ga-RM2阳性者中位PSA显著高于阴性者。作者认为68Ga-RM2-PET/CT值得进一步研究。

要点

  • 16例18FECH-PET/CT阴性或不确定的生化复发前列腺癌患者中,68Ga-RM2-PET/CT在10例(62.5%)发现可疑复发灶。
  • 68Ga-RM2阳性者中位PSA 6.8 ng/ml显著高于阴性者1.5 ng/ml(p=0.016)。
  • Gleason评分或同期抗雄激素治疗对复发灶检出无明显影响。

核心结论

  • 即使在18FECH-PET/CT阴性或不确定的已知生化复发高度选择患者中,68Ga-RM2-PET/CT仍能在多数病例中帮助定位前列腺癌复发。
  • 作者认为68Ga-RM2-PET/CT作为有前景的前列腺癌复发显像方法值得进一步研究。

研究设计与样本

  • 回顾性研究纳入16例生化复发前列腺癌男性,其中18FECH-PET/CT阴性14例、不确定2例,均行全身68Ga-RM2-PET/CT。
  • 18FECH-PET/CT至68Ga-RM2-PET/CT平均间隔6.1±6.8个月。
  • 初治为根治性前列腺切除术13例(81.3%)或放疗3例(18.7%);14/16例(87.5%)在68Ga-RM2-PET/CT前已因生化复发接受挽救治疗。
  • 68Ga-RM2-PET/CT时平均±标准差PSA为19.4±53.5 ng/ml(范围1.06-226.4 ng/ml)。

主要发现

  • 68Ga-RM2-PET/CT在10/16例(62.5%)显示至少一个局灶性异常摄取区,提示局部复发4例、淋巴结转移4例、骨转移1例、肺转移伴肺门淋巴结转移1例。
  • 10例阳性68Ga-RM2扫描中7例经手术切除及病灶组织学(2例)、定向治疗反应(2例)或进一步影像(3例)阳性确认。
  • 68Ga-RM2阳性者中位PSA为6.8 ng/ml(四分位距10.2 ng/ml),显著高于阴性者1.5 ng/ml(四分位距3.1 ng/ml;p=0.016)。
  • Gleason评分或同期抗雄激素治疗对复发灶检出无明显影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/BACKGROUND: [18F]fluoroethylcholine (18FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the 68Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive 18FECH-PET/CT. MATERIAL AND METHODS: In this retrospective study 16 men with biochemical PCa relapse and negative (n = 14) or inconclusive (n = 2) 18FECH-PET/CT underwent whole-body 68Ga-RM2-PET/CT. Mean time from 18FECH-PET/CT to 68Ga-RM2-PET/CT was 6.1 ± 6.8 months. Primary therapies in these patients were radical prostatectomy (n = 13; 81.3%) or radiotherapy (n = 3; 18.7%). 14/16 patients (87.5%) had already undergone salvage therapies because of biochemical relapse prior to 68Ga-RM2-PET/CT imaging. Mean ± SD PSA at 68Ga-RM2-PET/CT was 19.4 ± 53.5 ng/ml (range 1.06-226.4 ng/ml). RESULTS: 68Ga-RM2-PET/CT showed at least one region with focal pathological uptake in 10/16 patients (62.5%), being suggestive of local relapse (n = 4), lymph node metastases (LNM; n = 4), bone metastases (n = 1) and lung metastasis with hilar LNM (n = 1). Seven of ten positive 68Ga-RM2 scans were positively confirmed by surgical resection and histology of the lesions (n = 2), by response to site-directed therapies (n = 2) or by further imaging (n = 3). Patients with a positive 68Ga-RM2-scan showed a significantly higher median PSA (6.8 ng/ml, IQR 10.2 ng/ml) value than those with a negative scan (1.5 ng/ml, IQR 3.1 ng/ml; p = 0.016). Gleason scores or concomitant antihormonal therapy had no apparent impact on the detection of recurrent disease. CONCLUSION: Even in this highly selected population of patients with known biochemical recurrence but negative or inconclusive 18FECH-PET/CT, a 68Ga-RM2-PET/CT was helpful to localize PCa recurrence in the majority of the cases. Thus, 68Ga-RM2-PET/CT deserves further investigation as a promising imaging modality for imaging PCa recurrence.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wieser G, Popp I, Christian Rischke H, et al. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist 68Ga-RM2: Preliminary results in patients with negative or inconclusive [18F]Fluoroethylcholine-PET/CT. Eur J Nucl Med Mol Imaging. 2017. PMID: 28417160. doi:10.1007/s00259-017-3702-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。